What is Zegluxen®? Therapeutic indications
Zegluxen® is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) which improves glycaemic control by lowering fasting and postprandial blood glucose in patients with Type 2 diabetes mellitus (T2DM).1
Zegluxen® is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) which improves glycaemic control by lowering fasting and postprandial blood glucose in patients with Type 2 diabetes mellitus (T2DM).1
The Zegluxen® GLP-1 analogue binds to the GLP-1 receptor to elicit and increase in cAMP, stimulating glucose-dependent insulin secretion and lowering inappropriately high glucagon secretion.
Zegluxen® is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled Type 2 diabetes mellitus as an adjunct to diet and exercise.1
- As a monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
- In addition to other medicinal products for the treatment of diabetes.1
cAMP, cyclic adenosine monophosphate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, haemoglobin A1c; SmPC, Summary of Product Characteristics; T2DM, type 2 diabetes mellitus.
1. Zegluxen® (liraglutide) Summary of Product Characteristics.
000697548 | December 2024